A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

BACKGROUND: Despite widespread availability of direct-acting antivirals including generic formulations, limited progress has been made in the global adoption of hepatitis C virus (HCV) treatment. Barriers to treatment scale-up include availability and access to diagnostic and monitoring tests, healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Sunil S, Wagner-Cardoso, Sandra, Smeaton, Laura, Sowah, Leonard A, Wimbish, Chanelle, Robbins, Gregory, Brates, Irena, Scello, Christine, Son, Annie, Avihingsanon, Anchalee, Linas, Benjamin, Anthony, Donald, Nunes, Estevão Portela, Kliemann, Dimas A, Supparatpinyo, Khuanchai, Kityo, Cissy, Tebas, Pablo, Bennet, Jaclyn Ann, Santana-Bagur, Jorge, Benson, Constance A, Van Schalkwyk, Marije, Cheinquer, Nelson, Naggie, Susanna, Wyles, David, Sulkowski, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920770/
https://www.ncbi.nlm.nih.gov/pubmed/35026142
http://dx.doi.org/10.1016/S2468-1253(21)00397-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920770/
https://www.ncbi.nlm.nih.gov/pubmed/35026142
http://dx.doi.org/10.1016/S2468-1253(21)00397-6

Ejemplares similares